Skip to main content

Table 1 Baseline characteristics

From: Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies

  Dose escalation (n = 26) GIST expansion (n = 9)
Age 53.3 years (range: 23–71) 61.6 years (range 45–75)
Sex
 Female 10 (38.5%) 2 (22.2%)
 Male 16 (61.5%) 7 (77.8%)
ECOG PS
 0 4 0
 1 19 9
 2 3 0
Malignancy
 Melanoma 8 0
 RCC (clear cell) 5 0
 NSCLC 3 0
 GIST 3 9
 Other 7a 0
Prior treatment regimens (avg, range) 4 (0–11) 4 (1–6)
 Prior anti-CTLA4 1 0
 Prior imatinib 3 9
 Prior regorafenibb -- 8
 Prior sunitinibb -- 7
 Prior nilotinibb -- 3
 Prior sorafenibb -- 1
Molecular profile   
 KIT 8 9
  Exon 5 1 0
  Exon 9 1c 0
  Exon 10 4 0
  Exon 11 2 8c
  Exon 13 0 2c
  Exon 17 1c 2c
 NRAS 3 1
 TP53 3 0
 KDR 2 0
 MET 2 0
 PIK3CA 2 0
 KRAS 1 0
  1. ECOG PS Eastern cooperative group performance status, GIST gastrointestinal stromal tumor, RCC renal cell carcinoma, NSCLC non-small cell lung cancer
  2. aProstate, Mesothelioma, Osteosarcoma, Germ-cell tumor, Salivary duct, Renal medullary, Anal
  3. bPrior TKI exposure reported for GIST expansion only
  4. cRepresent patients with co-mutations